As demand for advanced therapies continues to surge, the biopharma industry is under pressure to innovate faster in high-risk areas like drug discovery and cell therapy. These fields face persistent challenges, such as high costs, long development timelines, and complex regulatory landscapes. To that end, MaxCyte has introduced a new high-throughput electroporation platform that streamlines genetic material delivery with speed, precision, and scalability.

This new platform can process up to 96 samples in under three minutes, allowing independent optimization and minimal waste. It’s designed to support seamless scalability from small-scale discovery to large-volume, GMP-compliant manufacturing, integrating with the MaxCyte ExPERT platform.

During this webinar, we’ll explore how the new software enables fine-tuned energy delivery across diverse cell types, including hard-to-transfect immune cells. We’ll also walk through real-world applications, such as optimizing non-viral CAR-T engineering using CRISPR-Cas9, demonstrating high-throughput efficiency, with consistent reproducibility.